Newark, New Castle, USA, May 23, 2023 (GLOBE NEWSWIRE) — The market analysis of the global neutrophilic dermatosis market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 6.5% by 2031.
Analysis of the global market for neutrophilic dermatosis indicates that during the forecast period, revenue share is likely to increase significantly. A set of skin conditions known as neutrophilic dermatoses are characterized by inflammation and neutrophil infiltration into the skin tissues.
Key Takeaways:
- The increasing number of patients with skin disorders is driving the market revenue share.
- Market revenue for neutrophilic dermatosis, collaboration, and collaborations between pharmaceutical corporations, research institutes, and healthcare organizations.
- The sweet syndrome is expected to register a revenue CAGR of 6.7% from 2023 to 2031.
Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/neutrophilic-dermatosis-market/8999
Neutrophilic Dermatosis Market Scope
Report Attribute | Details |
CAGR | 6.5% |
Base Year for Estimation | 2022 |
Forecast Period | 2023 to 2031 |
Historical Year | 2021 |
Segments Covered | Type, Drug Class, Route Of Administration, and Region |
Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Recent Development in the Neutrophilic Dermatosis Market:
- In September 2022, Spevigo (spesolimab) from Boehringer Ingelheim is the first medication to be licensed by the FDA to treat generalized pustular psoriasis (GPP) flares in adults. For the treatment of skin conditions caused by neutrophils, spesolimab is constantly being researched.
Competitive Landscape
A list of the top companies operating in the global market for neutrophilic dermatosis includes:
- Viatris Inc.
- Novartis AG
- Merck & Co. Inc.
- Allergan, Inc. (AbbVie. Inc)
- Torrent Pharmaceuticals Limited
- Fera Pharmaceuticals
Market Drivers and Restraints:
The global neutrophilic dermatosis market revenue is driven by rising concerns for skin diseases, their early diagnosis, and precise treatments. Furthermore, the rising disease awareness is leading to increasing research and development activities and many mergers and collaborations in this field. This results in market revenue growth.
However, due to the potential adverse effects and risk of infections, the neutrophilic dermatosis market revenue growth is expected to be restrained.
Market Segmentation:
- Based on type, the global neutrophilic dermatosis market is segmented into sweet syndrome, gyoderma gangrenosum, behçet syndrome, and neutrophilic eccrine hidradenitis.
- Based on drug class, the global neutrophilic dermatosis market is segmented into corticosteroids, antibiotics, immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), and others.
- Based on the route of administration, the neutrophilic dermatosis market is segmented into oral, topical, and others.
Segmentation By Type
Based on the types, the sweet syndrome segment dominates the global neutrophilic dermatosis market with a revenue CAGR of 6.7%. This sizable revenue share is attributed to its higher prevalence, recognized more frequently by healthcare professionals, are characterized by distinctive clinical features, such as fever and tender erythematous plaques.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/neutrophilic-dermatosis-market/8999
Regional Growth Analytics
Based on the region, North America, with a sizable revenue share, dominates the global neutrophilic dermatosis market. This significant rise in revenue share is attributed to the increasing disease prevalence due to evolving lifestyles, environmental factors, and genetic susceptibility. Moreover, demand for better diagnostic methods, efficient treatments, and specialized healthcare services is increased by the expanding patient population is rising market revenue growth.
Report Coverage
Growth Plus Reports conducted extensive market research on the neutrophilic dermatosis market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecast Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- Reimbursement Scenario
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL NEUTROPHILIC DERMATOSIS MARKET – ANALYSIS & FORECAST, BY TYPE
- Sweet Syndrome
- Gyoderma Gangrenosum
- Behçet Syndrome
- Neutrophilic Eccrine Hidradenitis
- Others
- GLOBAL NEUTROPHILIC DERMATOSIS MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
- Corticosteroids
- Antibiotics
- Immunosuppressants
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Others
- GLOBAL NEUTROPHILIC DERMATOSIS MARKET – ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
- Oral
- Topical
- Others
NEUTROPHILIC DERMATOSIS MARKET TOC
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8999
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse more latest healthcare reports:
Dental Apex Locator Market by Product Type (Equipment, Accessories), End User (Hospitals, Dental Clinics) – Global Outlook & Forecast 2021-2031
Specific Protein Testing Market by Application (Cardiovascular diseases, Immunity), Product Type (Cystatin C, Apolipoprotein E), Sample Type (Blood, Urine) End User (Hospital, Biotechnology Companies) – Global Outlook & Forecast 2023-2031
Dental Anesthetic Market by Type (Local, General), End User (Hospitals, Dental Clinics) – Global Outlook & Forecast 2021-2031
In Vitro Diagnostic Substrate Market by Substrate Type (TMB Substrate, PNPP (p-Nitrophenyl Phosphate, Disodium Salt) Substrate), Test Type (IHC Test, ELISA Test), Application (Oncology, Nephrology), End User (Hospital Laboratories, Diagnostic Centers) – Global Outlook & Forecast 2023-2031
Propranolol Drugs Market by Route of Administration (Oral Administration), Application (Hypertension, Angina), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.